36 completed, 13 terminated, 5 active not recruiting, 3 recruiting. 35 Phase 2, 25 Phase 1, 6 Not applicable, 1 Phase 3.
Follow Prolymphocytic Leukemia: new trials by email Literature Review of Prolymphocytic Leukemia trials Research Report on Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Observatory of Prolymphocytic Leukemia T Molecular caracterization - Prolymphocytic Leukemia, T-cell Leukemia | Active not recruiting | French Innovative Leukemia Organisation | 50 | 2020-07-01 | 2026-10-28 | |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-03-01 | 2017-09-27 | |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis - Anemia, Cancer Fatigue | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2015-12-18 | 2019-10-29 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Fludarabine, Cyclophosphamide, Total body irradiation - Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 | 2015-12-01 | 2022-11-03 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Selinexor, Ibrutinib, Pharmacological Study - Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Completed | Jennifer Woyach | 34 | 2015-06-09 | 2025-06-10 |
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma | Phase 2 | Withdrawn | James Blachly | 2015-03-12 | 2017-04-05 | |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL acalabrutinib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Acerta Pharma BV | 69 | 2014-12-22 | 2025-12-19 |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Acerta Pharma BV | 306 | 2014-01-30 | 2026-05-05 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
Showing 20 of 63. Sign in to see all of them.
Leukemia, Prolymphocytic (63) · Leukemia, Lymphocytic, Chronic, B-Cell (60) · Lymphoma, Mantle-Cell (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (31) · Lymphoma, Follicular (30) · Lymphoma, Large B-Cell, Diffuse (26) · Burkitt Lymphoma (25) · Lymphoma, B-Cell, Marginal Zone (25) · Leukemia, Myeloid, Acute (24) · Multiple Myeloma (22) · Lymphoma, Non-Hodgkin (21) · Hodgkin Disease (18) · Primary Myelofibrosis (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Waldenstrom Macroglobulinemia (16)
Hemic and Lymphatic Diseases (63) · Immune System Diseases (63) · Immunoproliferative Disorders (63) · Leukemia, Lymphoid (63) · Lymphatic Diseases (63) · Lymphoproliferative Disorders (63) · Neoplasms (63) · Neoplasms by Histologic Type (63) · Hematologic Diseases (61) · Chronic Disease (60) · Disease Attributes (60) · Leukemia, B-Cell (60) · Pathologic Processes (60) · Pathological Conditions, Signs and Symptoms (60) · Leukemia (59)
Mycophenolic Acid (18) · fludarabine phosphate (18) · Whole-Body Irradiation (17) · Cyclophosphamide (15) · Cyclosporine (14) · Cyclosporins (10) · Peripheral Blood Stem Cell Transplantation (8) · Rituximab (8) · fludarabine (8) · Sirolimus (5) · Antilymphocyte Serum (4) · Lenalidomide (4) · Tacrolimus (4) · ibrutinib (4) · Filgrastim (3)
Fred Hutchinson Cancer Center (14) · National Cancer Institute (NCI) (13) · Masonic Cancer Center, University of Minnesota (7) · Chinese PLA General Hospital (4) · M.D. Anderson Cancer Center (3) · Acerta Pharma BV (2) · City of Hope Medical Center (2) · German CLL Study Group (2) · Ohio State University Comprehensive Cancer Center (2) · Wake Forest University Health Sciences (2) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1) · French Innovative Leukemia Organisation (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (54) · China (4) · Germany (4) · Italy (4) · Denmark (3) · Canada (2) · Australia (1) · Austria (1) · France (1) · New Zealand (1) · Puerto Rico (1) · Switzerland (1) · United Kingdom (1)
David Maloney (3) · Jennifer Woyach, MD (3) · Mohamed Sorror (3) · Brenda Sandmaier (2) · Chitra Hosing (2) · Ryotaro Nakamura (2) · Amir Mortazavi, MD (1) · Amy E DeZern, MD (1) · Ann E. Dahlberg (1) · Ann Woolfrey (1) · Brenda Cooper, MD (1) · Claudio Brunstein, MD (1) · Claudio Brunstein, MD, PhD (1)
PMID 32499241, PMID 28714866, PMID 34515338, PMID 34608724, PMID 18698002, PMID 18997171, PMID 19706886, PMID 19826119, PMID 22259028, PMID 22289993, PMID 23512246, PMID 24474568, PMID 24990615, PMID 25317870, PMID 25444722, PMID 25596730, PMID 26182309, PMID 26451310, PMID 26641137, PMID 26853648, PMID 26943915, PMID 28270022, PMID 29263894, PMID 29599530, PMID 30530801, PMID 30562587, PMID 31076448, PMID 31088809, PMID 31248843, PMID 31815579, PMID 31876911, PMID 31915195, PMID 32245502, PMID 32603426, PMID 33492438, PMID 34735860, PMID 39563886, PMID 39716442, PMID 41043099, PMID 41044668, PMID 41804087, PMID 41915892
P30CA015704 (11), P01CA018029 (6), P30CA016058 (6), U01CA076576 (5), N01CM62207 (2), P01CA078902 (2), P30CA016672 (2), 2014 (1), 2023 (1), N01CM00070 (1), N01CM62202 (1), P01CA015396 (1), P50CA140158 (1), R01CA085748 (1), R21CA115048 (1)